Scrophularia buergeriana attenuates allergic inflammation by reducing NF-κB activation

Scrophularia buergeriana Miq. (Scrophulariaceae) (SB) has been used as an oriental medicine for the treatment of inflammatory diseases, such as neuritis and pharyngolaryngitis. We explored the therapeutic effects of S. buergeriana ethanol extract (SBE) on airway inflammation in ovalbumin (OVA)-induc...

Full description

Saved in:
Bibliographic Details
Published in:Phytomedicine (Stuttgart) 2020-02, Vol.67, p.153159-153159, Article 153159
Main Authors: Shin, Na-Rae, Lee, A. Yeong, Song, Jun-Ho, Yang, Sungyu, Park, Inkyu, Lim, Je-Oh, Jung, Tae-Yang, Ko, Je-Won, Kim, Jong-Choon, Lim, Kyung Seob, Lee, Min Young, Shin, In-Sik, Kim, Joong Sun
Format: Article
Language:English
Subjects:
Allergic asthma
Animals
Asthma - chemically induced
Asthma - drug therapy
Disease Models, Animal
Female
Hypersensitivity - drug therapy
Hypersensitivity - physiopathology
Immunoglobulin E - metabolism
Inflammation - drug therapy
Inflammation - metabolism
Lipopolysaccharides - pharmacology
Matrix Metalloproteinase 9 - metabolism
Matrix metalloproteinase-9
Mice
Mice, Inbred BALB C
NF-kappa B - metabolism
Nuclear factor kappa B
Ovalbumin - adverse effects
Phosphorylation - drug effects
Plant Extracts - pharmacology
Pro-inflammatory cytokine
RAW 264.7 Cells
Scrophularia - chemistry
Scrophularia buergeriana
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Scrophularia buergeriana Miq. (Scrophulariaceae) (SB) has been used as an oriental medicine for the treatment of inflammatory diseases, such as neuritis and pharyngolaryngitis. We explored the therapeutic effects of S. buergeriana ethanol extract (SBE) on airway inflammation in ovalbumin (OVA)-induced asthmatic mice and lipopolysaccharide (LPS)-stimulated RAW264.7 cells. Mice were intraperitoneally injected with OVA on days 0 and 14 to elevate the immune response. On days 21 to 23, the mice were challenged with OVA solution and SBE (20 and 40 mg/kg) was administered daily by oral gavage from days 18 to 23. RAW264.7 cells were pretreated with SBE 1 h before LPS stimulation. SBE administration effectively suppressed inflammatory cell infiltration, the expression of interleukin (IL)-5, IL-13, and IL-17, immunoglobulin E, and airway hyperresponsiveness in an OVA-induced allergic asthma model. A reduction in histological alterations, including airway inflammation and mucus hypersecretion, was observed. These effects of SBE were accompanied by a decrease in matrix metalloproteinase-9 (MMP-9) expression and nuclear factor kappa B (NF-κB) phosphorylation. These responses were observed in LPS-stimulated RAW264.7 cells. SBE treatment reduced the mRNA expression of tumor necrosis factor (TNF)-α, IL-6, and MMP-9, and NF-κB phosphorylation, in LPS-stimulated RAW264.7 cells. Our results indicated that SBE effectively attenuated airway inflammation in an OVA-induced allergic asthma model. These properties of SBE were thought to be involved in the suppression of NF-κB phosphorylation, suggesting that the material has the potential to regulate the development of allergic asthma. [Display omitted]
ISSN:0944-7113
1618-095X
DOI:10.1016/j.phymed.2019.153159